Choices of pharmacologic therapies for pulmonary arterial hypertension (PAH) are ideally guided by high-level evidence. Th e objective of this guideline is to provide clinicians advice regarding pharmacologic therapy for adult patients with PAH as informed by available evidence.
For treatment naive PAH patients with WHO
FC I symptoms, we suggest continued monitoring for the development of symptoms that would signal disease progression and warrant the initiation of pharmacotherapy (Grade CB) . 5 . We suggest that patients at risk for the development of PAH (eg, patients with systemic sclerosis or the presence of a known mutation placing the patient at risk for PAH) be monitored for the development of symptoms of PAH (Grade CB) .
6. We suggest also that contributing causes of PH (eg, sleep apnea and systemic hypertension) in patients with PAH be treated aggressively (Grade CB) .
Symptomatic Patients With PAH

Vasoreactivity Testing and Use of Calcium Channel Blockers
7.
We suggest that patients with PAH, in the absence of contraindications, should undergo acute vasoreactivity testing using a short-acting agent at a center with experience in the performance and interpretation of vasoreactivity testing (Grade CB) .
Remark: Contraindications to acute vasoreactivity testing include a low systemic blood pressure, low cardiac output or the presence of FC IV symptoms. Acute vasoreactivity testing may be complicated by hypotension, and the misinterpretation of results may result in the inappropriate exposure of patients to the risks of a treatment trial with calcium channel blockers (CCBs) without the possibility of clinical benefi t. Vasoreactivity testing should be performed by individuals with appropriate training in test performance and interpretation.
We recommend ambrisentan to improve 6-min walk distance (6MWD) (Grade 1C
) .
11-12.
We suggest bosentan to delay time to clinical worsening (Grade CB) and improve cardiopulmonary hemodynamics. 13 . We suggest macitentan to delay the time to clinical worsening (Grade CB) .
14. We recommend sildenafi l to improve 6MWD (Grade 1C) .
We suggest tadalafi l to improve 6MWD (Grade CB
16-19. We suggest riociguat to improve 6MWD
(Grade CB) , improve WHO FC (Grade CB) , delay the time to clinical worsening (Grade CB) and improve cardiopulmonary hemodynamics.
We suggest also that parenteral or inhaled prostanoids not be chosen as initial therapy for treatment naive PAH patients with WHO FC II symptoms or as second line agents for PAH patients with WHO FC II symptoms who have not met their treatment goals (Grade CB
Patients With WHO FC III Symptoms:
For treatment-naive PAH patients with WHO FC III symptoms who are not candidates for, or who have failed CCB therapy, we advise monotherapy be initiated with a currently approved ETRA, a PDE5 inhibitor, or the soluble guanylate cyclase stimulator riociguat. More specifi cally in these patients: 21 . We recommend the use of bosentan to improve 6MWD (Grade 1B) .
22-23.
We suggest the use of bosentan to decrease hos pitalizations related to PAH in the short-term (Grade 2C) , and to improve cardiopulmonary hemodynamics.
We recommend the use of ambrisentan to improve 6MWD (Grade 1C
25-26. We suggest macitentan to improve WHO FC
(Grade CB) and delay the time to clinical worsening (Grade CB) .
27-29.
We recommend the use of sildenafi l to improve 6MWD (Grade 1C) and to improve WHO FC (Grade CB) . We suggest the use of sildenafi l to improve cardiopulmonary hemodynamics.
30-33.
We suggest the use of tadalafi l to improve 6MWD (Grade CB) , to improve WHO FC (Grade CB) , to delay time to clinical worsening (Grade CB) and to improve cardiopulmonary hemodynamics. 34-37. We suggest riociguat to improve 6MWD (Grade CB) , improve WHO FC (Grade CB) , delay the time to clinical worsening (Grade CB) and improve cardiopulmonary hemodynamics.
For treatment naive PAH patients with WHO FC III symptoms who have evidence of rapid progression of their disease, or other markers of a poor clinical prognosis, we advise consideration of initial treatment with a parenteral prostanoid. More specifi cally in these patients: 38-40. We suggest continuous IV epoprostenol to improve FC (Grade CB) , improve 6MWD (Grade CB) , and improve cardiopulmonary hemodynamics.
We suggest continuous IV treprostinil to improve 6MWD (Grade CB
42-43.
We suggest continuous subcutaneous treprostinil to improve 6MWD (Grade CB) and improve cardiopulmonary hemodynamics.
For PAH patients in WHO FC III who have evidence of progression of their disease, and/or markers of poor clinical prognosis despite treatment with one or two classes of oral agents, we advise consideration of the addition of a parenteral or inhaled prostanoid. More specifi cally in these patients: 44-46. We suggest IV epoprostenol to improve WHO FC (Grade CB) , improve 6MWD (Grade CB) , and improve cardiopulmonary hemodynamics.
47-48. We suggest IV treprostinil to improve 6MWD
(Grade CB) and improve cardiopulmonary hemodynamics. 49 . In patients with PAH who remain symptomatic on stable and appropriate doses of an endothelin receptor antagonist (ETRA ) or a PDE5 inhibitor, we suggest the addition of inhaled treprostinil to improve 6MWD (Grade 2C) .
Remark: Th e usual initial dose of inhaled treprostinil is 3 inhalations (18 m g) every 6 h. However, optimal eff ect of inhaled treprostinil may require titrating treprostinil doses up to 9 inhalations (54 m g) every 6 h.
50-51.
In patients with PAH who remain symptomatic on stable and appropriate doses of an ETRA or a PDE5 inhibitor, we suggest the addition of inhaled iloprost to improve WHO FC (Grade CB) and delay the time to clinical worsening (Grade CB) .
Patients With WHO FC IV Symptoms:
For treatment naive PAH patients in WHO FC IV, we advise initiation of monotherapy with a parenteral prostanoid agent. More specifi cally in these patients:
[ 1 4 6 # 2 C H E S T A U G U S T 2 0 1 4 ] 52-54. We suggest continuous IV epoprostenol to improve WHO FC (Grade CB) , improve 6MWD (Grade CB) , and improve cardiopulmonary hemodynamics.
We suggest continuous IV treprostinil to improve 6MWD (Grade CB
56-57.
For treatment naive PAH patients in WHO FC IV who are unable or do not desire to manage parenteral prostanoid therapy, we advise treatment with an inhaled prostanoid in combination with an ETRA. More specifi cally in these patients: 58-59. We suggest bosentan to improve 6MWD (Grade 2B) and cardiopulmonary hemodynamics.
60-61. We suggest inhaled iloprost to improve 6MWD (Grade CB) , and improve WHO FC (Grade CB
We suggest inhaled treprostinil (in combination only) to improve 6MWD (Grade CB
PAH Patients on Established PAH-Specifi c Th erapy:
63. In PAH patients initiating therapy with IV epoprostenol, we suggest against the routine simultaneous initiation of bosentan (Grade CB) .
For WHO FC III or IV PAH patients with unacceptable clinical status despite established PAH-specifi c monotherapy, we advise addition of a second class of PAH therapy to improve exercise capacity. Such patients are ideally evaluated at centers with expertise in the evaluation and treatment of complex patients with PAH. More specifi cally:
64. In patients with PAH who remain symptomatic on stable doses of an ETRA or a PDE5 inhibitor, we suggest the addition of inhaled iloprost to improve 6MWD (Grade CB) .
In patients with PAH who remain symptomatic on stable doses of an ETRA or a PDE5 inhibitor, we recommend the addition of inhaled treprostinil to improve 6MWD (Grade 1C) .
In PAH patients who remain symptomatic on stable doses of established IV epoprostenol, we
suggest the addition of sildenafi l or up titration of epoprostenol to improve 6MWD (Grade CB) .
67-70.
In patients with PAH who remain symptomatic on stable doses of bosentan, ambrisentan or an inhaled prostanoid, we suggest the addition of the soluble guanylate cyclase stimulator riociguat to improve 6MWD (Grade CB) , WHO FC (Grade CB) and cardiopulmonary hemodynamics and to delay the time to clinical worsening (Grade CB) .
71-73.
In patients with PAH who remain symptomatic on stable doses of a PDE5 inhibitor or an inhaled prostanoid we suggest macitentan to improve 6MWD (Grade CB) , WHO FC (Grade CB) and to delay the time to clinical worsening (Grade CB) .
For WHO FC III or IV PAH patients with unacceptable or deteriorating clinical status despite established PAH-specifi c therapy with two classes of PAH pharmacotherapy, we suggest addition of a third class of PAH therapy (Grade CB) .
Remark: Such patients are ideally evaluated at centers with expertise in the evaluation and treatment of complex patients with PAH.
Specifi c Patient Situations
Pregnancy
In patients with PAH, we suggest that pregnancy be avoided (Grade CB) .
Remark: Estrogen-containing contraceptives may increase the risk of VTE and are not recommended for women with childbearing potential who have PAH. Additionally, the ETRA bosentan may decrease the effi cacy of hormonal contraception. Bosentan, ambrisentan, macitentan and riociguat are contraindicated in pregnancy (category X; evidence of serious fetal abnormalities) and dual mechanical barrier contraceptive techniques are recommended in female patients of childbearing age taking these medications.
76.
When pregnancy does occur, we suggest care at a pulmonary hypertension center, using a multidisciplinary approach including the pulmonary hypertension, the high-risk obstetrical and cardiovascular anesthesiology services (Grade CB) .
Altitude and Air Travel
77. In patients with PAH, we suggest that exposure to high altitude be avoided, and that supplemental oxygen be used as needed during altitude exposure or air travel to maintain oxygen saturations greater than 91% (Grade CB) .
Introduction
Pulmonary arterial hypertension (PAH) remains a highly morbid disease with high mortality. Despite a recent growth in therapeutic options, clinicians and their patients continue to struggle with questions regarding pharmacologic treatments. Th is document aims to provide practical guidance to clinicians faced with common questions regarding the use of available pharmacotherapies for the treatment of patients with PAH. We sought to apply a rigorous process to the collection and assessment of evidence and to make guideline recommendations informed and supported by that evidence. Unfortunately, rigorous data needed to address important questions faced by clinicians when treating patients with PAH are oft en absent or insufficient. We therefore present a hybrid document. When suffi ciently strong evidence from randomized clinical trials addressing a clinically important question is available, we have based our guideline recommendation statements upon them. When evidence is absent or insuffi cient to provide evidence-based guideline recommendation statements, we provide our best expert advice as consensus statements with the goal of helping clinicians navigate important therapeutic questions.
We emphasize that accurate and timely diagnosis must precede therapy for PAH. Pulmonary hypertension (PH) is categorized according to fi ve groups. In addition to PAH (group 1), PH may be due to left -sided heart disease (group 2), lung diseases and/or hypoxia (group 3), chronic thromboembolic pulmonary hypertension (CTEPH, group 4), or unclear multifactorial mechanisms (group 5). 1 It is a critical responsibility of the clinician to ensure that an accurate diagnosis is established, and readers are referred to previously published guidelines by the American College of Chest Physicians (CHEST) and other organizations on the evaluation of PH and diagnosis of PAH. 2 -4 Th e recommendations in this guideline are for the treatment of patients with PAH and should not be applied to the treatment of patients with other types of PH. None of the drugs currently approved for therapy for PAH are approved for therapy for patients with PH due to left -sided heart disease or chronic hypoxemic lung disease. Th e limited evidence available regarding the use of these drugs in patients with PH due to left -sided heart disease or hypoxemic lung disease has not demonstrated benefi t overall and in some cases suggests the potential for signifi cant harm. Further, failure to correctly identify or address the cause of PH may deny the patient benefi cial treatment (eg, for left -sided heart disease). Although one drug approved for treatment of PAH has been shown to be benefi cial in patients with CTEPH not amenable to surgical thromboendarterectomy, surgery remains the optimal therapy for many patients with CTEPH, and patients should be evaluated promptly for consideration of thromboendarterectomy at a center suffi ciently experienced with this procedure. 5 Standards for the development of clinical guidelines have evolved, and the approach to the grading of evidence has become more rigorous since the last CHEST guideline on PAH. 2 , 6 As a result, readers may note lower grades assigned to recommendations in this guideline update as compared with the grading of statements recommending similar actions in prior CHEST guidelines on PAH or related recommendations of other organizations. Th is may seem paradoxical at fi rst, as the evidence upon which the recommendations are based remains, in many cases, largely the same. Th e change in grading refl ects the more rigorous standard now being applied by CHEST to the evaluation of evidence. Further, some equivalent and parallel trials of individual drugs have been conducted and reported independently, whereas others were reported as single larger investigations. We recognize that this may infl uence assessments of the overall strengths of evidence available, but we judged it best to adhere to a consistent approach based upon how studies were accepted by the US Food and Drug Administration (FDA) and reported.
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Although patients meeting diagnostic criteria for PAH share many clinical characteristics, we emphasize that a wide variety of underlying diseases and risk factors may lead to PAH, likely with diff ering etiologic mechanisms. Similarly, all patients classifi ed as having idiopathic PAH by the exclusion of known risk factors for PAH may not suff er from the same pathobiologic processes. Clinical trials of PAH-specifi c therapies have generally enrolled patients under the broad defi nition of PAH, although with an overall predominance of patients with either idiopathic PAH or PAH associated with systemic sclerosis. It is important to recognize the limitations in knowledge regarding the effi cacy of available agents in all forms of PAH. Further, with the exception of calcium channel blockers (CCBs), we lack eff ective means of predicting which patients with PAH may benefi t from individual agents.
Th is guideline addresses only drugs that were approved by the US FDA for the management of PAH symptoms at the time that the guideline was developed (with the exception of CCBs, which we include because of their continued importance as PAH-specifi c therapy for a small but important subgroup of patients with PAH). Further, as the US FDA has approved drugs for PAH therapy in part according to a patient's World Health Organization (WHO) functional classifi cation, and because we believe it will best assist clinicians to use this guideline, we have organized our recommendations around such a classifi cation. We recognize the limitations of the WHO functional classifi cation 7 and that other variables must be considered simultaneously (such as exercise capacity, right ventricular function, hemodynamics, economic and other social factors, quality of life, and, most importantly, patient preferences). We recognize also the limitations of the hemodynamic, exercise capacity (6-min walk distance [6MWD]), 8 and clinical worsening end points we present in this guideline for clinicians to consider when choosing pharmacologic therapy. Our knowledge of the relative importance of these end points and how changes in each or groups of end points impact patients' lives is limited. 9 Although we stress the importance of the involvement of clinicians with expertise in the evaluation and treatment of PH in the management of patients with PAH, the target audience for this guideline is the whole community of clinicians involved in the collaborative care of adult patients with PAH (including cardiologists, nurses, nurse practitioners, primary care internists and family physicians, pulmonologists, and rheumatologists). We do not address therapy for children, and readers are referred to the guidelines of other professional societies. 10 "Supportive" pharmacologic therapies (eg, diuretics, supplemental oxygen, and so forth) are important in the management of patients with PAH in addition to the "PAH-specifi c" drugs addressed in this document. We have not performed an updated literature review regarding such supportive care and refer readers to prior CHEST guideline statements regarding this important aspect of PAH care. We remind clinicians of the importance of carefully reviewing prescribing information and consulting reliable resources to check for drug-drug interactions.
No approved therapy for PAH has been shown to prevent progression of the underlying pulmonary vascular disease. PAH remains an incurable disease; currently, clinicians attempt to manage it with pharmacotherapy. Although we believe the outlook for a patient with newly diagnosed PAH has improved, it remains far from adequate or acceptable.
We hope that many of the gaps in the evidence base refl ected in this document will be fi lled before the next update to this guideline. We call upon the community of academic and industry-based researchers in this fi eld to choose carefully those studies that will answer the most important clinical questions so as to best use the limited but generous eff orts of our patients, who risk their well-being as volunteer participants in clinical studies.
Methods
Th e goal of this CHEST guideline project was to produce clinically relevant and useful recommendations on medical therapies for PAH for clinicians who treat adult patients with PAH. Health-care providers should use these guidelines to assist patients with treatment choices that optimize benefi ts and minimize harms and burdens.
In 2011, the Institute of Medicine (IOM) released new guideline standards 6 that required signifi cantly more scientifi c rigor and high-quality evidence to be considered trustworthy. CHEST is committed to upholding the IOM standards in guideline development. However, CHEST realizes clinicians may need to communicate important messages that do not have the necessary associated evidence to be called a "guideline" by the new IOM standards.
In a number of areas related to therapy for PAH, we found the available evidence to be insuffi cient to support the more rigorous process necessary to uphold the IOM standards for guidelines. To provide guidance to clinicians in such areas lacking suffi cient evidence, the CHEST practice of developing trustworthy consensus statements was used. Th is hybrid methodology accommodates "very low" or "insuffi cient" levels of evidence and incorporates both guidelines and consensus statements in the same project. Th e following document refl ects this hybrid approach and follows the standards of the organization to produce credible guidance for physicians and other members of the health-care team.
Composition and Selection of Topic Panel Members
For this CHEST guideline project, a nonconfl icted chair was appointed by the organization's Guidelines Oversight Committee (GOC). Th e chair had the authority to nominate (subject to GOC review and approval) other panelists for specifi c roles, including participation on the project executive committee and topic editors for the various sections based on drug classes.
All panelists (consisting of the chair, executive committee members, and topic editors) were approved by the CHEST GOC aft er review of their qualifi cations and confl ict of interest (COI) disclosures. For one of the 12 approved panelists (who had relevant confl icts), a COI management program was followed according to the procedures of the GOC, including abstention from voting on areas related to confl icts ( e- Table 1 ). Th roughout the guideline development process all panelists were required to report any new activities that might involve potential COIs for review and approval by the GOC. ( Table 1 ) were used by the EPC to select articles for inclusion at both the title and abstract and full-text screening stages. Titles and abstracts were examined independently by two reviewers from the EPC for potential relevance. Articles included by the reviewers underwent full-text screening, in which paired researchers from the EPC independently reviewed articles and indicated which ones to include for data extraction. Any disagreements were reconciled through a third party arbitrator at the EPC. All screening decisions were made and tracked in the DistillerSR database (Evidence Partners).
In the literature search performed by the EPC, there were 8,256 citations gathered (3,919 MEDLINE, 36 Cochrane, 4,301 EMBASE). Aft er 1,626 duplicate articles were removed and 46 articles were added manually, a total of 6,676 citations were identifi ed. Th e screening of abstracts excluded 5,352 articles, and the inclusion criteria excluded 1,127 additional articles. Th e remaining 197 articles representing 186 unique studies passed full-text screening. Of these, 46 articles (37 studies) were relating to monotherapy or combination therapy for PAH using prostanoids, endothelin antagonists, or phosphodiesterase inhibitors. Th e search for RCTs of the use of CCBs for the therapy for PAH found no studies. As noted above, because CCBs continue to be used and play an important role in the therapy for a small subset of patients with PAH, the guideline panel chose to develop consensus statements on the basis of available nonrandomized studies in this one class of drugs to provide clinically helpful advice for their use.
For the review performed for macitentan and riociguat, there were four citations gathered for macitentan and four citations gathered for riociguat. Aft er the same PICOTS criteria ( Table 1 ) was used by the panel to select articles for inclusion at both the title and abstract and full-text screening stages, one study remained for macitentan and one study remained for riociguat.
Summarizing Evidence and Drafting
Recommendations
Data Extraction and Quality Assessment: Based on the included studies, the panel constructed data tables that summarized key data elements of each included article. Data elements in the tables included sample size and description, setting description, intervention name and dose, outcome name and values, and associated significance levels. Th e critical appraisal quality score of each individual study was determined from the EPC based on the Cochrane Risk of Bias tool. 12 Two raters from the EPC independently evaluated each study, and diff erences were resolved by consensus. Summary ratings of good, fair, or poor were assigned to each individual study by the EPC based on the tool. For the two articles included from the panel review of macitentan and riociguat, the panel used the same Cochrane Risk of Bias tool to assess study quality. Th e panel placed the quality scores for each included article as another data element in the constructed data tables.
Meta-analyses and Pooling of Outcomes:
Th e data extracted by the panel in the evidence tables from the included studies were pooled according to comparable interventions and outcomes. Th e panel included only those studies that addressed the use of therapies currently approved by the US FDA.
A meta-analysis using random eff ects was performed by the panel methodologist to quantitatively synthesize available outcome data by intervention. Th e relative eff ects for pooled studies were estimated using an OR for discrete outcomes and mean diff erence for continuous outcomes. Also, statistical heterogeneity was assessed with an I 2 statistic. Meta-analyses were performed and forest plots were constructed using Review Manager, version 5.1 (Th e Nordic Cochrane Centre, Th e Cochrane Collaboration).
Evaluating Quality of Bodies of Evidence:
Th e rating of the quality of the entire body of evidence for each intervention and outcome comparison was assessed by the panel methodologist. Grades of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology was used for summarizing and grading the pooled evidence. Ratings of the pooled evidence started as high quality and were downgraded based on the domains of risk of bias, precision, consistency, directness, and publication bias. 13 A letter grade (A, B, C or Insuffi cient) was assigned by the panel to each pooled estimate based on the CHEST grading system 14 ( e-Appendix 1 ) as indicated by the evidence level of the body of literature supporting each intervention and outcome comparison. To be considered at least C-level evidence, two or more studies addressing a particular intervention and outcome were needed. 15 However, pooled estimates were downgraded from higher evidence levels into an "Insuffi cient" level of evidence if indicated by domains set forth by a GRADE methodologic approach. A meta-analysis was performed only when two or more studies addressed a particular intervention and outcome. All performed meta-analyses are available in e- Figure 1 , and profi led evidence is available in e- Table 2 . Th e study data that these pooled estimates were based upon are available in e- Table 3 . Where the evidence level was determined "A, " "B, " or "C, " an evidence-based guideline was pursued. Where the evidence level was determined "Insuffi cient, " a consensus statement was pursued. In these instances, "CB" (consensus-based) was considered the grade. All areas considering CCBs as a therapy were graded as CB because of insuffi cient evidence. Separately, a number grade (1 or 2) was assigned by the panel to each draft ed recommendation based on the CHEST grading system 14 ( e-Appendix 1 ). Th e number grade is a refl ection of the topic editors' consensus on the balance of benefi ts and harms of treatment, based on their expert clinical knowledge, experience, and interpretation of the evidence in the gathered literature. Consensus in this instance was determined through open discussion and debate between the two authoring topic editors for each section.
Topic editors draft ed initial recommendations, which were combined with the corresponding grade and presented to the entire panel via webinar. Following subsequent group discussions and wording refi nements, the entire panel met in Philadelphia in May 2013 to discuss organization and consistency of the recommendations. Aft er the recommendations were in fi nal draft form, they were presented to the entire panel in a formal consensus development process based on the Delphi technique. 16 Consensus Development: Th e purpose of the Delphi technique in this project was to achieve formal consensus on each recommendation while accounting for group interaction bias and maintaining anonymity among respondents. Using an online survey ( www. surveymonkey.com ), panelists were requested to vote representing their level of agreement with each presented recommendation based on a fi ve-point scale derived from the GRADE grid. 17 Also, each panelist could provide open-ended feedback on each recommendation with suggested wording edits or general remarks.
Each presented recommendation or consensus-based statement was required to achieve panel consensus (80% of the votes in agreement) to be included in the fi nal manuscript, along with a response rate of Ն 75% of survey respondents. Otherwise, the recommendation was revised or dropped by the author, based on the anonymous and collated open-ended feedback from the respondents in the survey. If the recommendation or consensus-based statement was revised, the author had the choice to resubmit it to the next round of the survey for voting again by the entire panel. Th e process was continued until consensus had been reached on each of the presented statement. When the statements that achieved panel consensus had been identifi ed through this process, the executive committee then reviewed each chapter's fi nal recommendations and consensusbased statements to resolve any areas of confusion or inconsistency before a fi nal manuscript was submitted for the peer review process.
Review by CHEST and External Reviewers
When the fi nal manuscript was completed and endorsed by the executive committee, the manuscript underwent peer review process by the organization to consider content, methods, and adherence to the organization's processes. Reviewers were self-nominated and vetted through the same COI disclosure and management process as the panelists. Reviewers were either members of the organization's Cardiovascular and Pulmonary Vascular NetWork, the CHEST GOC, or the CHEST Board of Regents. In addition, CHEST primary reviewers from the GOC and Board of Regents and a reviewer selected by the Editor of the CHEST journal reviewed the entire article for fl uency and cohesiveness.
Pharmacologic Th erapy for PAH in Adults
Lacking head-to-head comparisons of pharmacologic agents for the treatment of PAH, and because of their diff ering burdens and risks to patients, we recommend that drug therapy be chosen on the basis of a methodical evaluation of disease severity and the risk for further short-term deterioration. Th e optimal method of evaluation has not been studied. Despite variability in clinicians' approaches, 7 the WHO FC ( Table 2 ) 18 provides a patient-centered means of assessing disease Class II: Patients with PH resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope.
Class III: Patients with PH resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope.
Class IV: Patients with PH with inability to carry out any physical activity without symptoms. These patients manifest signs of right-sided heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.
PH 5 pulmonary hypertension. Adapted from Rich et al. 18 impact on a patient's life. Th e rarity of PAH makes its recognition and diff erentiation from other causes of pulmonary hypertension less familiar to most clinicians. Because both an accurate diagnosis and familiarity with the choice of drugs best suited to individual patients are essential to guide therapy, we believe that patients in whom a diagnosis of PAH has been made or is being considered be evaluated at a center with demonstrated expertise and established infrastructure for the management of patients with PAH with advanced disease or complex medical problems. Such evaluations may be diffi cult because of the distance to such a center, in which case initial telephone consultation between physicians may be a practical approach with plans for in-person evaluation of the patient at the center with advanced PAH expertise as soon as possible. Ongoing care of patients with PAH is best served through close collaboration between locally available physicians and colleagues at centers with advanced expertise in PAH care. Patients with PAH may also have conditions that contribute to the development or worsening of pulmonary hypertension (eg, obstructive sleep apnea or systemic hypertension). Th ese conditions should be optimally treated.
Recommendation
Symptomatic Patients With PAH
Vasoreactivity Testing and Use of CCBs
CCBs are a recommended treatment of pulmonary arterial hypertension (PAH) in a defi ned subset of patients who have a specifi c biomarker that predicts the response to therapy. Patients likely to respond to CCBs can be identifi ed by hemodynamic testing with shortacting vasodilators at the time of initial evaluation. 19 No other clinical characteristic or baseline hemodynamic feature predicts those patients who will respond.
Recommendation
7.
Remark: Contraindications to acute vasoreactivity testing include a low systemic BP, low CO, or the presence of FC IV symptoms. Acute vasoreactivity testing may be complicated by hypotension, and the misinterpretation of results may result in the inappropriate exposure of patients to the risks of a treatment trial with CCBs without the possibility of clinical benefi t. Vasoreactivity testing should be performed by individuals with appropriate training in test performance and interpretation.
Th e responses to inhaled nitric oxide 20 or intravenously administered acetylcholine, 21 tolazoline, 22 epoprostenol, 23 or adenosine 24 all identify patients with the ability to acutely lower their PAP. Th e consensus defi nition of acute vasoreactivity is a fall in mPAP . 10 mm Hg, to an mPAP , 40 mm Hg, with an unchanged or increased CO. 3 Data on long-term clinical benefi t (survival out to 5-18 years) come from two large prospective uncontrolled studies. 25 
PAH-Specifi c Pharmacotherapies
Endothelin Receptor Antagonists
Bosentan: Four double-blind placebo-controlled studies of bosentan for the treatment of PAH overall found that bosentan resulted in improvements in exercise capacity, hemodynamics, and time to clinical worsening, with a signifi cantly decreased hazard for hospitalization compared with placebo. Th e fi rst study enrolled 32 patients with WHO FC III or IV disease due to IPAH or PAH associated with systemic sclerosis. 29 Aft er 12 weeks of treatment, the mean placebo-corrected improvement in 6MWD was 76 m (95% CI, 12-139; P 5 .021) in patients treated with bosentan. In addition, the CI was 1.0 L/min/m 2 (95% CI, 0.6-1.4; P , .0001) greater in patients given bosentan than in those who received placebo, and the placebo-corrected improvement in PVR was 2 415 dyn/s/cm 5 ( 2 608 to 2 221, P 5 .0002) in the bosentan group.
A larger RCT of 213 patients had similar entry criteria and found that aft er 16 weeks of treatment, the 6MWD among bosentan-treated patients was an average of 44 m greater than patients who had received placebo (95% CI, 21-67 m; P , .001). Th is study included mortality and hospitalization for PH as part of the secondary end point of the number of clinical worsening events, which was defi ned as the combined end point of death, lung transplantation, hospitalization for pulmonary hypertension, lack of clinical improvement or worsening leading to discontinuation from study drug, need for epoprostenol therapy, or atrial septostomy. 30 Over 28 weeks of follow-up, there were two deaths (3%) in the placebo group, which was not signifi cantly diff erent from the combined bosentan groups ( Macitentan: A multicenter, double-blind, randomized, placebo-controlled, event-driven, phase 3 trial investigated whether long-term treatment with macitentan reduces clinical worsening events among patients with PAH. 34 Patients Ն 12 years of age who had IPAH or PAH related to connective tissue disease, repaired congenital systemicto-pulmonary shunts, HIV infection, or drug use or toxin exposure were eligible for inclusion. Confi rmation of PAH by right-sided heart catheterization was required, as was a 6MWD Ն 50 m and WHO FC II, III, or IV. At the time of entry into the study, . 60% of patients were on treatment with oral phosphodiesterase-5 (PDE5) inhibitors, oral or inhaled prostanoids, CCBs, or l -arginine. Patients receiving IV or subcutaneous prostanoids were excluded. Patients were randomly assigned in a 1:1:1 ratio to receive placebo once daily (n 5 250), macitentan at a once-daily dose of 3 mg (n 5 250), or macitentan at a once-daily dose of 10 mg (n 5 242). Th e composite primary end point was the time from the initiation of treatment to the fi rst event related to PAH (worsening of PAH, initiation of treatment with IV or subcutaneous prostanoids, lung transplantation, or atrial septostomy) or death from any cause up to the end of treatment. Secondary end points included the change from baseline to month 6 in the 6MWD, the percentage of patients with an improvement in WHO FC at month 6, death due to PAH or hospitalization for PAH up to the end of treatment, and death from any cause up to the end of treatment and up to the end of the study. . Th e number of patients in the placebo, 3-mg macitentan, and 10-mg macitentan groups who discontinued the study drug owing to adverse events was 31 (12.4%), 34 (13.6%), and 26 (10.7%), respectively. Th e incidences of peripheral edema and of alanine aminotransferase or aspartate aminotransferase levels that were more than three times the upper limit of the normal range were similar across the three groups. As compared with patients who received placebo, higher percentages of patients in the two macitentan groups had nasopharyngitis, headache, and anemia. Th ree patients, one in each group, discontinued treatment because of anemia.
Phosphodiesterase Type-5 Inhibitors
Sildenafi l: A placebo-controlled study randomized 278 treatment-naive patients to placebo or 20, 40, or 80 mg of sildenafi l three times daily for 12 weeks. Patients were predominantly in WHO FC II or III. Th e primary end point (a placebo-adjusted increase in the 6MWD) was seen with each sildenafi l dose, and the drug was approved by the US FDA at the 20 mg tid dose. Improvements in the 6MWD were not statistically diff erent across the dose range studied of 20 to 80 mg tid. Cardiopulmonary hemodynamics were measured at baseline and aft er 12 weeks of treatment; compared with placebo, mPAP and PVR were lower in patients who received any of the three doses of sildenafi l. Th e proportion of patients who improved at least one WHO FC was signifi cantly greater in each sildenafi l treatment group than in the placebo group. 35 Only 7% of patients treated with placebo improved their FC, compared with 28%, 36%, and 42% of patients treated with 20, 40, and 80 mg tid of sildenafi l, respectively. Th ere was no diff erence observed in the number of clinical worsening events (which were defi ned as the occurrence of death, transplantation, hospitalization for PAH, or the initiation of additional therapies for PAH).
Tadalafi l: A placebo-controlled trial randomized 405 patients with PAH to placebo or tadalafi l 2.5, 10, 20, or 40 mg once daily for 16 weeks. 36 Approximately one-half of the patients in the study were treatment naive and the other one-half had background therapy with an ETRA that was continued during the study. Th e primary outcome measure set as a P , .01 diff erence in placebo-adjusted increase in 6MWD aft er 16 weeks of treatment was met only in patients in the highestdose treatment group. Th e mean placebo-corrected increase in 6MWD was 33 m for the combined group of patients receiving 40 mg tadalafi l once daily (with and without background ETRA therapy). 36 Treprostinil: Randomized, placebo-controlled, doubleblind trials of IV treprostinil 39 and subcutaneous treprostinil 40 and a nonblinded, placebo-controlled randomized trial of inhaled iloprost have likewise supported treatment benefi ts in patients with PAH. Specifi cally, one placebo-controlled, randomized trial of IV treprostinil in treatment-naive PAH FC III and IV patients 39 enrolled 44 study patients with IPAH or familial PAH and randomized them in a 2:1 fashion to either IV treprostinil (n 5 30) or IV placebo (n 5 14). Iloprost: A 3-month, randomized, double-blind, placebocontrolled, multicenter trial of iloprost via inhalation six to nine times per day used a composite primary end point of a 10% improvement in the 6MWD and WHO FC improvement in the absence of clinical deterioration or death. 41 One hundred forty-six patients with PAH and 57 with CTEPH were included. Th e composite end point was achieved in 17% of treated patients compared with 5% in patients receiving placebo ( P 5 .007). Th e treatment eff ect on the 6MWD was a mean increase of 36 m in the overall population in favor of iloprost ( P 5 .004) and 59 m in the subgroup of 102 patients with IPAH.
Side eff ects more commonly reported with the use of IV epoprostenol or treprostinil than placebo include headache, jaw pain, diarrhea, abdominal pain, anorexia, vomiting, photosensitivity, cutaneous fl ushing, and arthralgias. 37 -40 , 42 -57 Other adverse eff ects associated with IV prostanoid use include infection of the catheter site, catheter-related bloodstream infection and sepsis, and malfunction of the drug-delivery system. 37 , 38 , 46 , 47 , 49 , 58 -63 Site pain occurs frequently in those on subcutaneous treprostinil. 40 , 64 , 65 Inhaled prostanoids result in cough, headache, fl ushing, nausea, and syncope more commonly than placebo with iloprost 41 and cough, headache, and fl ushing more commonly than placebo with treprostinil. 66 
Soluble Guanylate Cyclase Stimulator
Riociguat: A 12-week, double-blind, randomized, placebo-controlled trial of the soluble guanylate cyclase stimulator riociguat was conducted in patients with PAH. 5 Th e study enrolled 443 patients with symptomatic PAH (idiopathic, familial, or associated with connective tissue disease, congenital heart disease, portal hypertension with liver cirrhosis, or anorexigen or amphetamine use), with a PVR of . 300 dyn/s/cm 5 , an mPAP of Ն 25 mm Hg, and a 6MWD of 150 to 450 m. Patients who were receiving no other treatment of PAH and patients who were receiving treatment with ETRAs or prostanoids (excluding IV prostanoids) were eligible; patients who were receiving PDE5 inhibitors were excluded. Oral anticoagulant agents, as well as diuretics and supplemental oxygen at stable doses, were permitted. Patients were randomly assigned, in a 2:4:1 ratio, to one of three regimens: placebo, oral riociguat administered in doses that were individually adjusted for each patient up to 2.5 mg tid, or oral riociguat administered in individually adjusted doses that were capped at 1.5 mg tid. Dose adjustments during the fi rst 8 weeks of the study were made based on the patient's systolic BP (with increases if trough systolic BP was . 95 mm Hg) and signs or symptoms of hypotension. Th e primary end point was the change from baseline in 6MWD. Secondary end points included changes from baseline to the end of week 12 in PVR, N-terminal pro-BNP levels, WHO FC, time to clinical worsening (defi ned as the occurrence of death, atrial septostomy, heart/lung transplantation, hospitalization for PAH, initiation of new PAH-specifi c medication or adjustment in prostanoid therapy, or worsening 6MWD or WHO FC), Borg dyspnea score, and quality-of-life assessments. At week 12, the 6MWD had increased from baseline by a mean of 30 m in the 2.5-mg maximum group and had decreased by a mean of 6 m in the placebo group ( P , .001). Pulmonary vascular resistance decreased by 223 dyn/s/cm 5 in the 2.5-mg maximum group, compared with 9 dyn/s/cm 5 in the placebo group ( P , .001). Statistically signifi cant improvements in other hemodynamic variables, including mPAP and CO, were also evident in patients treated with riociguat. Improvements in N-terminal pro-BNP levels, WHO FC, and score on the Borg dyspnea scale were also seen in the riociguat-treated group as compared with placebo, as was a signifi cantly lower incidence of events indicating clinical worsening in the 2.5-mg maximum group than in the placebo group. Th e most frequently occurring serious adverse events were syncope (in 1% of the patients in the 2.5-mg maximum group vs 4% in the placebo group), worsening pulmonary hypertension (in , 1% of the patients in the 2.5-mg maximum group vs 2% in the placebo group), chest pain (in 1% of the patients in both the 2.5-mg maximum group and the placebo group), and right ventricular failure (in 1% of the patients in both groups). Drug-related serious adverse events in the 2.5-mg maximum group included three cases of syncope (in 1% of the patients) and single cases of increased hepatic enzyme levels, dizziness, presyncope, acute renal failure, and hypotension (in a total of 0.4% of the patients). 10. We recommend ambrisentan to improve 6MWD (Grade 1C) .
Patients
11-12.
We suggest bosentan to delay time to clinical worsening (Grade CB) and improve cardiopulmonary hemodynamics.
13. We suggest macitentan to delay the time to clinical worsening (Grade CB) .
We suggest tadalafi l to improve 6MWD
(Grade CB) . ETRAs and PDE5 inhibitors should be initiated at the approved doses. Although the US FDA-approved dose of sildenafi l for treatment of PAH is 20 mg tid, titration of therapy up to 80 mg tid has been done in clinical trials and a dose response in hemodynamic response has been noted. In patients who fail to demonstrate and maintain an adequate clinical response to 20 mg sildenafi l tid, we recommend consideration of increasing the dose in 20 mg increments to a maximum of 80 mg tid or adding another agent. Treatment with more than the recommended dose of tadalafi l (40 mg once daily) has not been studied and is not recommended. Treatment with bosentan . 125 mg bid is associated with greater incidence of transaminase elevation and is not recommended. As treatment with 10 mg of ambrisentan resulted in greater improvement in 6MWD than 5 mg without an observed increase in adverse eff ects, 33 patients should be started at the 5-mg daily dose of ambrisentan and, if well tolerated and treatment goals have not been reached, increase to the 10-mg dose. Th e dose of riociguat requires dose titration. Based upon currently available evidence showing a risk of systemic hypotension when coadministered with a PDE5 inhibitor, male patients treated with riociguat should also be cautioned not to use PDE5 inhibitors for erectile dysfunction.
16-19. We suggest riociguat to improve 6MWD
Recommendations
For treatment-naive PAH patients with WHO FC III symptoms who are not candidates for, or who have failed CCB therapy, we advise monotherapy be initiated with a currently approved ETRA, a PDE5 inhibitor, or the soluble guanylate cyclase stimulator riociguat. More specifi cally in these patients:
21. We recommend the use of bosentan to improve 6MWD (Grade 1B) .
22-23.
We suggest the use of bosentan to decrease hospitalizations related to PAH in the short-term (Grade 2C) , and to improve cardiopulmonary hemodynamics.
24.
We recommend the use of ambrisentan to improve 6MWD (Grade 1C) .
25-26.
We suggest macitentan to improve WHO FC (Grade CB) and delay the time to clinical worsening (Grade CB) .
27-29.
30-33.
We suggest the use of tadalafi l to improve 6MWD (Grade CB) , to improve WHO FC (Grade CB) , to delay time to clinical worsening (Grade CB) and to improve cardiopulmonary hemodynamics.
34-37. We suggest riociguat to improve 6MWD
Because of the paucity of comparative eff ectiveness data among the diff erent agents, none can be defi nitively recommended preferentially. Inhaled prostanoids (iloprost, treprostinil) have shown less consistent and robust eff ects than continually infused prostanoid therapy described earlier but may be appropriate initial therapy in select patients with contraindications to oral agents and/or who cannot be treated with continuous parenteral agents. Because of the ease of administration, oral agents are generally preferred as initial therapy unless the patient has more severe symptoms or if there is a worrisome rate of symptom progression, in which case parenteral therapies might be considered. Most clinical data derive from individuals with IPAH, and extrapolation of effi cacy may be problematic in other PAH subgroups. In some, such as PAH associated with the systemic sclerosis spectrum of diseases, response to pharmacologic intervention has been studied and generally is less impressive than in patients with IPAH. IV prostanoid therapies require high degrees of patient training, motivation, and support to be successful. IV prostanoid therapies should only be managed by centers with the experience and staffi ng required to provide 24-h support to complicated patients on these medications. Each of the following parenteral prostanoids has been studied and approved for use in patients with PAH with WHO FC III symptoms.
Recommendations
For treatment naive PAH patients with WHO FC III symptoms who have evidence of rapid progression of their disease, or other markers of a poor clinical prognosis, we advise consideration of initial treatment with a parenteral prostanoid. More specifi cally in these patients:
38-40. We suggest continuous IV epoprostenol to improve FC (Grade CB) , improve 6MWD (Grade CB) , and improve cardiopulmonary hemodynamics.
41. We suggest continuous IV treprostinil to improve 6MWD (Grade CB) .
42-43.
Each of the parenteral prostanoids has been studied and approved for use in patients with PAH in WHO FC III. Considering the greater risk, complexity of administration, and cost of parenteral prostanoids, these agents should generally be used as initial therapy for FC III patients who exhibit rapid disease progression or other markers of worse clinical outcomes. Th ey have not generally been adequately studied as up-front combination treatment with oral ETRA or PDE5 inhibitors but may be considered as add-on therapy when patients receiving one or two oral agents fail to meet clinical goals or when they exhibit clinical worsening.
Recommendations
For PAH patients in WHO FC III who have evidence of progression of their disease, and/or markers of poor clinical prognosis despite treatment with one or two classes of oral agents, we advise consideration of the addition of a parenteral or inhaled prostanoid. More specifi cally in these patients:
44-46. We suggest IV epoprostenol to improve WHO FC (Grade CB) , improve 6MWD (Grade CB) , and improve cardiopulmonary hemodynamics.
47-48. We suggest IV treprostinil to improve 6MWD
(Grade CB) and improve cardiopulmonary hemodynamics.
49. In patients with PAH who remain symptomatic on stable and appropriate doses of an ETRA or a PDE5 inhibitor, we suggest the addition of inhaled treprostinil to improve 6MWD (Grade 2C) .
50-51.
Patients With WHO FC IV Symptoms: Most experts in the fi eld consider IV epoprostenol the therapy of choice for WHO FC IV patients based on extensive clinical experience and the fi ndings of improved survival 37 in a single study. Rapid onset of action and titratability of this form of therapy to the severity of the class IV patient's disease make this preferable over oral PAH-specifi c therapies.
RCT data 39 are limited, but considerable clinical experience supports the exercise benefi ts of IV treprostinil. Data suggest that this therapy may have a greater risk of catheter-associated infection (with both gram-positive and gram-negative organisms) 59 -63 than IV epoprostenol, and it may require higher doses (ng/kg/min) to achieve comparable effi cacy.
Prostanoid therapies require patients who are able to manage the complex delivery systems and comply with the therapies to ensure safety. Family support is of paramount importance in the decision to initiate inhaled or infused prostanoid therapy. In addition, prostanoid therapies require proper infrastructure and specialty center care. In centers without the proper infrastructure to ensure safe delivery of these therapies, it is recommended that patients be referred to an experienced pulmonary hypertension center. Severely ill or unstable patients with class IV PAH should be admitted to the hospital for initiation of prostanoid therapy to ensure stabilization and improvement in clinical status and to educate both the patient and family about the safe administration of these therapies to ensure safe transition to outpatient therapy. Listing for lung transplantation should be considered for these patients with WHO FC IV PAH. (Grade CB) , and improve cardiopulmonary hemodynamics.
Recommendations
55. We suggest continuous IV treprostinil to improve 6MWD (Grade CB) .
56-57.
In general, the magnitude of impact of inhaled prostanoids on these outcomes has been less than that seen with parenteral prostanoid therapy, and these therapies are generally believed to be less optimal in sicker (WHO FC IV) patients. Inhaled iloprost has been studied in patients who remain symptomatic (94% WHO FC III) while receiving a stable dose of bosentan for at least 3 months. 67 Although improvements aft er 12 weeks in 6MWD, hemodynamics, and time to clinical worsening were observed, the small number of FC IV patients studied makes recommendation of this therapy for these patients tenuous. 67 Inhaled treprostinil has been suggested to sustain 6MWD improvements primarily in WHO FC III patients (on background oral monotherapy), with very limited data for FC IV patients. 68 Th erapy for patients with WHO FC IV status that does not include a prostanoid should be reserved only for those patients unable to safely self-administer or without the social support to handle the rigors of these therapies safely, or in patients who have expressed suffi ciently informed preferences to forgo such therapies. FC IV patients who forgo prostanoid therapies must be made aware that transplant centers may not consider them appropriate candidates for lung transplantation. In such patients, some experts would consider up-front initiation of two oral therapies, although supporting evidence is limited. 52
Recommendations
For treatment naive PAH patients in WHO FC IV who are unable or do not desire to manage parenteral prostanoid therapy, we advise treatment with an inhaled prostanoid in combination with an ETRA. More specifi cally in these patients:
58-59. We suggest bosentan to improve 6MWD (Grade 2B) and cardiopulmonary hemodynamics.
60-61. We suggest inhaled iloprost to improve 6MWD
(Grade CB) , and improve WHO FC (Grade CB) . Th e majority of patients were diagnosed with idiopathic PAH (n 5 27) or PAH associated with a collagen vascular disease (n 5 6). Although both groups showed improved 6MWD, WHO FC, and total pulmonary resistance, there was no signifi cant diff erence in the primary outcome of change in total pulmonary resistance from baseline to 16 weeks in the epoprostenol/ bosentan group vs the epoprostenol/placebo group (mean Ϯ SEM, 2 36.3% Ϯ 4.3% vs 22.6% Ϯ 6.2%; P 5 .08). Th ere were more serious adverse events observed in the combination therapy group.
We suggest inhaled treprostinil (in combination only) to improve 6MWD (Grade CB
Addition of Inhaled Prostanoid to Stable Oral
Monotherapy: Two prospective double-blind placebocontrolled RCTs compared addition of an inhaled prostanoid against an inhaled placebo in patients with PAH on stable monotherapy with an ETRA or PDE5 inhibitor. Th e majority of patients were diagnosed with idiopathic PAH or PAH associated with a collagen vascular disease.
One randomized 235 patients with PAH with WHO FC III (98%) or IV symptoms and a 6MWD of 200 to 450 m while treated for at least 3 months with bosentan (70%) or sildenafi l (30%) to inhaled treprostinil ( Յ 54 μg) or inhaled placebo four times daily. 66 Inhaled treprostinil improved exercise capacity (placebo-corrected median change from baseline in peak 6MWD of 20 m at week 12; P , .001) and quality of life and was safe and welltolerated. Patients appeared more likely to benefi t if the pretreatment 6MWD was , 300 m before the addition of inhaled treprostinil. Th e usual initial dose of inhaled treprostinil was three inhalations (18 μg) every 6 h. However, the optimal eff ect of inhaled treprostinil oft en required titration of treprostinil doses up to nine inhalations (54 μg) every 6 h over a period of 2 weeks.
Another study of 67 patients with PAH who remained symptomatic (94% FC III) despite bosentan therapy randomized participants to inhaled iloprost or placebo. 67 When compared with placebo aft er 12 weeks, iloprost showed a tendency for improved exercise capacity compared with placebo ( P 5 .051) and signifi cant improvement in WHO FC ( P 5 .002) and in the occurrence of worsening events ( P 5 .022) and was safe and well tolerated.
Addition of Sildenafi l to Stable IV Epoprostenol:
One prospective double-blind placebo-controlled RCT compared the eff ect of the addition of sildenafi l or a placebo in patients with PAH on stable doses of IV epoprostenol (generally between 10 ng/kg/min and 50 ng/kg/min) over 16 weeks. 48 Th e trial included 267 patients with PAH, most with WHO FC II (25%) or III (65%) symptoms and a 6MWD of 100 to 450 m while treated with stable doses of IV epoprostenol, who had oral sildenafi l or placebo added. Th e majority had idiopathic PAH. Th e usual initial dose of sildenafi l was 20 mg by mouth every 8 h. However, the optimal eff ect of sildenafi l oft en required titrating sildenafi l doses up to 80 mg every 8 h over a period of 8 weeks. Transient changes in epoprostenol dose, typically in increments of 1 to 2 ng/kg/min every 1 to 2 weeks, were made in response to inadequate therapeutic responses.
Compared with placebo, sildenafi l was associated with an adjusted treatment diff erence in 6MWD of 1 28.8 m (95% CI, 13.9-43.8 m). Th ere were improvements also in hemodynamic measurements and time to clinical worsening. Th e use of sildenafi l in addition to IV epoprostenol was associated with more headaches and dyspepsia. Patients appeared more likely to benefi t if the pretreatment 6MWD was . 325 m before the addition of sildenafi l. Data from RCTs are not available to inform the addition of a third pharmacologic class of PAH medication. However, addition of a third class of PAH medication usually indicates poor functional status. In this setting, we believe that treatment with a parenteral prostanoid therapy must be considered.
Addition of a Long
Th e recommendations for combination therapy should be used as general guidelines until more is known about which combinations are most effi cacious and the optimal timing of combining therapies is available. Until then, an individualized approach should be used by a practitioner who has experience using combination therapy for PAH. In general, escalation of therapy and referral for lung transplantation evaluation should occur when a patient has evidence of disease progression on combination therapy. As noted above, whether established drugs are best continued with the initiation of new agents requires study. 69 Following is an update to that section of the document. Many patients with PAH are women of childbearing age. Th e hemodynamic demands of pregnancy are substantial and include an increase of 30% to 50% in blood volume, a similar increase in CO, a 10-to 20-beat/min increase in heart rate, an increase in stroke volume, and decreases in both systemic vascular resistance and BP. 69 , 70 Th ese hemodynamic changes begin during the fi rst trimester and peak at 20 to 24 weeks of gestation. During labor, there are further increases in CO, and the BP also increases with uterine contractions. Immediately postpartum there are marked volume shift s, with cardiac fi lling pressures increasing dramatically as a result of decompression of the vena cava and the return of uterine blood into the systemic circulation. Th e hemodynamic changes associated with pregnancy regress by approximately 6 weeks aft er delivery. Th e physiologic changes induced by pregnancy impose a marked hemodynamic stress in women with IPAH, leading to a previously estimated 30% to 50% mortality rate. 71 , 72 More recent data indicate that the outcome of pregnancy in PAH has improved (a 12% maternal mortality rate was reported in a recent survey 73 ), at least when PAH is well controlled. However, pregnancy remains associated with a substantial mortality risk. Because of potential maternal and fetal morbidity and mortality, most experts recommend eff ective contraception and consideration of early termination if pregnancy occurs in a patient with PAH. 3 , 74 , 75 In addition to the hemodynamic stresses of pregnancy, hormonal changes during and immediately following pregnancy may also be detrimental from a pathophysiologic standpoint. Anecdotal experience suggests that even if a woman successfully delivers a term infant, her pulmonary hypertension may progress during pregnancy and remain worse aft er pregnancy.
Furthermore, there appears to be an increased incidence of small-for-gestational-age infants born to women with IPAH, 76 as well as an increased incidence of congenital anomalies.
Th ere are several reports of successful treatment of pregnant patients with IPAH with chronic IV epoprostenol, 77 -80 inhaled nitric oxide, 81 -83 and oral CCBs. 73 , 84 In general, current management includes early hospitalization for closer monitoring once the fetus is viable, supportive therapy with cautious fl uid management, supplemental oxygen, diuretics, and dobutamine, as needed. In addition, the use of a pulmonary artery catheter for close hemodynamic monitoring may be helpful.
Recommendations for the optimal mode of delivery remain controversial; early concerns of high mortality with cesarean section delivery led to an emphasis on vaginal delivery, and a series of seven women with severe pulmonary hypertension who were successfully delivered by the vaginal route has been described. 85 Successful treatment during cesarean section delivery has also been reported, which may partly be due to the changes in the selection and use of anesthetics. 86 In a meta-analysis of the outcome of pulmonary vascular disease and pregnancy from 1978 through 1996, Weiss and colleagues reported a maternal mortality rate of 36% in Eisenmenger syndrome, 30% in IPAH, and 56% in associated pulmonary hypertension. 72 Similarly, although acknowledging that data on outcomes are limited, previous guidelines from the American Heart Association and the American College of Cardiology recommend that pregnancy be avoided or terminated in women with cyanotic congenital heart disease, pulmonary hypertension, and Eisenmenger syndrome.
Recommendations
75.
In patients with PAH, we suggest that pregnancy be avoided (Grade CB) .
Remark: Estrogen-containing contraceptives may increase the risk of VTE and are not recommended for women with childbearing potential who have PAH.
Additionally, the ETRA bosentan may decrease the effi cacy of hormonal contraception. Bosentan, ambrisentan, macitentan and riociguat are contraindicated in pregnancy (category X; evidence of serious fetal abnormalities) and dual mechanical barrier contraceptive techniques are recommended in female patients of childbearing age taking these medications.
When pregnancy does occur in patients with
PAH, we suggest care at a pulmonary hypertension center, using a multidisciplinary approach including the pulmonary hypertension, the high-risk obstetrical and cardiovascular anesthesiology services (Grade CB) .
Altitude and Air Travel
We discourage exposure to high altitude ( . about 1,829 m [6,000 ft ] above sea level), as it may produce hypoxic pulmonary vasoconstriction and further compromise oxygen transport. 87 Supplemental oxygen should be used to maintain saturations . 91% (although fi rm parameters have not been established in PAH). Air travel can be problematic for patients with PAH, as commercial aircraft s are typically pressurized to the equivalent of approximately 8,000 feet above sea level. High-altitude simulation testing may be useful to more accurately determine the need for and required rate of supplemental oxygen administration during airfl ight. 88 , 89 Recommendation 77. In patients with PAH, we suggest that exposure to high altitude be avoided, and that supplemental oxygen be used as needed during altitude exposure or air travel to maintain oxygen saturations . 91% (Grade CB) .
Remark : Patients with borderline oxygen saturations at sea level may require 3-4 L per minute of supplemental oxygen under these conditions, and those already using supplemental oxygen at sea level should increase their oxygen fl ow rate on commercial aircraft .
Vaccinations
Because of the potentially devastating eff ects of respiratory infections, immunization against infl uenza and pneumococcal pneumonia is recommended.
Recommendation
78.
In patients with PAH, we suggest maintaining current immunization against infl uenza and pneumococcal pneumonia (Grade CB) .
Surgery
Invasive procedures and surgery can be associated with increased operative and perioperative risks. 90 Patients with severe PAH are particularly prone to vasovagal events, leading to syncope, cardiopulmonary arrest, and death. Cardiac output is particularly dependent upon heart rate in this situation, and the bradycardia and systemic vasodilatation accompanying a vasovagal event can result in hypotension. Heart rate should be monitored during invasive procedures, with ready availability of an anticholinergic agent. Oversedation can lead to ventilatory insufficiency and precipitate clinical deterioration. The induction of anesthesia and intubation can be particularly problematic for patients with PAH because it can induce vasovagal events, hypoxemia, hypercarbia, and shift s in intrathoracic pressureassociated changes in cardiac fi lling pressures. Caution should be used with laparoscopic procedures in which carbon dioxide is used for abdominal insuffl ation, as absorption can produce hypercarbia, which is a pulmonary vasoconstrictor. Although itself not usually a contraindication to surgery, the potential inhibitory eff ects of prostanoid drugs on platelet function should be noted.
Recommendation
79.
In patients with PAH, we suggest avoiding nonessential surgery, and when surgery is necessary we suggest care at a pulmonary hypertension center, using a multidisciplinary approach including the pulmonary hypertension team, the surgical service, and cardiovascular anesthesiology with careful monitoring and management of clinical status, oxygenation and hemodynamics postoperatively (Grade CB) .
Conclusions
Th e options for pharmacotherapy in patients with PAH include several drug classes and delivery routes. Th e choice of therapy should be made by experienced clinicians and must be based upon an appropriately established diagnosis and evaluation of the patient's disease severity. Available evidence is suffi cient to inform a limited number of strong guideline recommendation statements regarding the eff ect of a specifi c therapy or combination of therapies on select outcomes in distinct groups of patients defi ned according to disease severity. Where current evidence is insuffi cient to inform strong guideline recommendations, expert consensus may provide reasonable advice in evaluating available data and reasonable therapeutic choices. Well-designed studies are needed to compare approaches to therapy in specifi c groups of patients. As such information and new therapies become available, a reassessment of appropriate clinical advice for the pharmacologic therapy for adult patients with PAH will be required. 
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